Alimera Sciences Stock Price, News & Analysis (NASDAQ:ALIM)

$1.25 0.00 (0.00 %)
(As of 02/23/2018 06:00 AM ET)
Previous Close$1.25
Today's Range$1.22 - $1.26
52-Week Range$1.03 - $1.72
Volume45,031 shs
Average Volume123,556 shs
Market Capitalization$86.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79

About Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences logoAlimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company's product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.

Receive ALIM News and Ratings via Email

Sign-up to receive the latest news and ratings for ALIM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biopharmaceuticals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ALIM
CUSIPN/A
Phone678-990-5740

Debt

Debt-to-Equity Ratio-0.71%
Current Ratio4.84%
Quick Ratio4.65%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$34.33 million
Price / Sales2.52
Cash FlowN/A
Price / CashN/A
Book Value($0.67) per share
Price / Book-1.87

Profitability

Trailing EPS($0.31)
Net Income$-33,170,000.00
Net Margins-55.29%
Return on EquityN/A
Return on Assets-28.43%

Miscellaneous

Employees125
Outstanding Shares69,150,000

Alimera Sciences (NASDAQ:ALIM) Frequently Asked Questions

What is Alimera Sciences' stock symbol?

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

How were Alimera Sciences' earnings last quarter?

Alimera Sciences, Inc. (NASDAQ:ALIM) released its earnings results on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01. The biopharmaceutical company had revenue of $10.40 million for the quarter, compared to the consensus estimate of $10.20 million. The company's quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) EPS. View Alimera Sciences' Earnings History.

When will Alimera Sciences make its next earnings announcement?

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for Alimera Sciences.

Where is Alimera Sciences' stock going? Where will Alimera Sciences' stock price be in 2018?

3 brokers have issued 1 year price objectives for Alimera Sciences' stock. Their forecasts range from $3.00 to $5.00. On average, they expect Alimera Sciences' share price to reach $4.00 in the next year. View Analyst Ratings for Alimera Sciences.

What are Wall Street analysts saying about Alimera Sciences stock?

Here are some recent quotes from research analysts about Alimera Sciences stock:

  • 1. According to Zacks Investment Research, "Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. " (1/8/2018)
  • 2. Cowen Inc analysts commented, "Adaptimmune reported Q3 financials including net loss of $1MM and a cash balance." (11/2/2017)

Who are some of Alimera Sciences' key competitors?

Who are Alimera Sciences' key executives?

Alimera Sciences' management team includes the folowing people:

  • Richard S. Eiswirth Jr., President, Chief Financial Officer (Age 47)
  • Rich Cockrell, President
  • C. Daniel Myers, Chief Executive Officer (Age 62)
  • Kenneth E. Green Ph.D., Senior Vice President, Chief Scientific Officer (Age 57)
  • David R. Holland, Senior Vice President - Sales and Marketing (Age 52)
  • Philip Ashman, Senior Vice President, European Managing Director (Age 51)
  • Mark J. Brooks, Independent Director (Age 48)
  • Brian K. Halak Ph.D., Independent Director (Age 45)
  • Peter J. Pizzo III, Independent Director (Age 49)

Who owns Alimera Sciences stock?

Alimera Sciences' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (9.85%), Stonepine Capital Management LLC (5.15%) and Renaissance Technologies LLC (0.60%). Company insiders that own Alimera Sciences stock include Armistice Capital Master Fund, Armistice Capital, Llc, C Daniel Myers, LP Bavp, Philip Ashman and Richard S Eiswirth Jr. View Institutional Ownership Trends for Alimera Sciences.

Who sold Alimera Sciences stock? Who is selling Alimera Sciences stock?

Alimera Sciences' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have sold Alimera Sciences company stock in the last year include C Daniel Myers, Philip Ashman and Richard S Eiswirth Jr. View Insider Buying and Selling for Alimera Sciences.

Who bought Alimera Sciences stock? Who is buying Alimera Sciences stock?

Alimera Sciences' stock was purchased by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Armistice Capital LLC. Company insiders that have bought Alimera Sciences stock in the last two years include Armistice Capital Master Fund and Armistice Capital, Llc. View Insider Buying and Selling for Alimera Sciences.

How do I buy Alimera Sciences stock?

Shares of Alimera Sciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alimera Sciences' stock price today?

One share of Alimera Sciences stock can currently be purchased for approximately $1.25.

How big of a company is Alimera Sciences?

Alimera Sciences has a market capitalization of $86.43 million and generates $34.33 million in revenue each year. The biopharmaceutical company earns $-33,170,000.00 in net income (profit) each year or ($0.31) on an earnings per share basis. Alimera Sciences employs 125 workers across the globe.

How can I contact Alimera Sciences?

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]


MarketBeat Community Rating for Alimera Sciences (ALIM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  153 (Vote Underperform)
Total Votes:  317
MarketBeat's community ratings are surveys of what our community members think about Alimera Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Alimera Sciences (NASDAQ:ALIM) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$4.00
Price Target Upside: 233.33% upside233.33% upside222.58% upside166.67% upside

Alimera Sciences (NASDAQ:ALIM) Consensus Price Target History

Price Target History for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ:ALIM) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018HC WainwrightReiterated RatingBuy$5.00MediumView Rating Details
11/2/2017CowenReiterated RatingBuyN/AView Rating Details
4/27/2017Rodman & RenshawInitiated CoverageBuy -> Buy$4.00HighView Rating Details
3/4/2016Cantor FitzgeraldLower Price TargetBuy$6.00 -> $5.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Alimera Sciences (NASDAQ:ALIM) Earnings History and Estimates Chart

Earnings by Quarter for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ ALIM) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/27/2018($0.03)N/AView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$9.50 million$9.78 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.05)($0.04)$10.20 million$10.40 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.08)($0.10)$8.80 million$6.62 millionViewListenView Earnings Details
3/1/2017Q4 2016($0.07)($0.10)$10.60 million$10.70 millionViewListenView Earnings Details
11/2/2016Q316($0.11)($0.16)$10.53 million$8.30 millionViewN/AView Earnings Details
8/3/2016Q2($0.19)($0.17)$8.42 million$3.80 millionViewN/AView Earnings Details
5/4/2016Q1($0.19)($0.22)$5.83 million$5.80 millionViewN/AView Earnings Details
3/2/2016Q4 2015($0.23)($0.24)$5.82 millionViewN/AView Earnings Details
11/5/2015Q315($0.22)($0.21)$6.96 million$6.90 millionViewN/AView Earnings Details
8/10/2015Q215($0.22)($0.25)$6.49 million$5.80 millionViewListenView Earnings Details
5/7/2015Q115($0.24)($0.27)$3.90 million$3.90 millionViewN/AView Earnings Details
3/4/2015Q414($0.16)($0.28)$5.11 million$1.70 millionViewN/AView Earnings Details
11/6/2014Q314($0.70)($0.22)$3.75 million$2.40 millionViewN/AView Earnings Details
8/7/2014Q214($0.23)($0.15)$2.70 million$2.19 millionViewN/AView Earnings Details
5/8/2014Q114($0.25)($0.20)$1.15 million$2.08 millionViewN/AView Earnings Details
2/27/2014Q413($0.29)($0.24)$0.75 million$0.94 millionViewN/AView Earnings Details
11/11/2013Q313($0.30)($0.26)$0.38 million$0.76 millionViewN/AView Earnings Details
8/12/2013Q2 2013($0.24)($0.30)$3.00 million$0.18 millionViewN/AView Earnings Details
5/9/2013Q1 2013($0.26)($0.27)ViewN/AView Earnings Details
3/21/2013Q4 2012($0.23)($0.17)ViewN/AView Earnings Details
11/7/2012Q312($0.19)($0.17)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.19)($0.15)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.14)($0.14)ViewN/AView Earnings Details
3/8/2012($0.24)($0.19)ViewN/AView Earnings Details
11/3/2011($0.19)($0.21)ViewN/AView Earnings Details
8/4/2011($0.18)($0.17)ViewN/AView Earnings Details
5/5/2011($0.20)($0.15)ViewN/AView Earnings Details
2/10/2011($0.22)($0.20)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.26)($0.20)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.26)($0.20)ViewN/AView Earnings Details
6/3/2010Q1 2010($0.49)($2.35)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Alimera Sciences (NASDAQ:ALIM) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.27 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS

Dividends

Dividend History for Alimera Sciences (NASDAQ:ALIM)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Alimera Sciences (NASDAQ ALIM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 14.70%
Institutional Ownership Percentage: 46.22%
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)
Insider Trades by Quarter for Alimera Sciences (NASDAQ:ALIM)

Alimera Sciences (NASDAQ ALIM) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/6/2018Armistice Capital Master FundMajor ShareholderBuy20,000$1.14$22,800.00View SEC Filing  
2/2/2018Armistice Capital, LlcMajor ShareholderBuy8,000$1.16$9,280.00View SEC Filing  
1/19/2018C. Daniel MyersCEOSell52,900$1.20$63,480.00101,511View SEC Filing  
1/19/2018Philip AshmanSVPSell25,500$1.20$30,600.0012,750View SEC Filing  
1/19/2018Richard S Eiswirth JrInsiderSell13,410$1.20$16,092.0084,779View SEC Filing  
1/17/2018C. Daniel MyersCEOSell52,900$1.23$65,067.00154,411View SEC Filing  
1/17/2018Philip AshmanSVPSell25,500$1.23$31,365.0038,250View SEC Filing  
1/17/2018Richard S Eiswirth JrInsiderSell14,494$1.23$17,827.6298,619View SEC Filing  
3/10/2017C. Daniel MyersCEOSell21,172$1.39$29,429.08180,861View SEC Filing  
9/15/2016Richard S Eiswirth JrInsiderSell51,471$1.51$77,721.2186,445View SEC Filing  
4/21/2016L.P. BavpMajor ShareholderSell478,673$2.59$1,239,763.074,477,291View SEC Filing  
12/16/2015Richard S. Eiswirth, Jr.CFOSell46,669$2.31$107,805.3934,974View SEC Filing  
12/8/2015James E FlynnInsiderBuy272,249$3.01$819,469.49View SEC Filing  
12/3/2015James E FlynnInsiderBuy243,252$3.00$729,756.00View SEC Filing  
10/30/2015James E FlynnInsiderBuy16,542$3.00$49,626.00View SEC Filing  
10/28/2015James E FlynnInsiderBuy59,342$3.00$178,026.00View SEC Filing  
10/26/2015James E FlynnInsiderBuy60,364$3.00$181,092.00View SEC Filing  
10/21/2015James E FlynnMajor ShareholderBuy160,684$3.00$482,052.00View SEC Filing  
10/20/2015James E FlynnMajor ShareholderBuy100,130$3.00$300,390.00View SEC Filing  
10/19/2015James E FlynnMajor ShareholderBuy129,226$2.92$377,339.92View SEC Filing  
10/15/2015Richard S. Eiswirth, Jr.CFOSell13,625$2.69$36,651.2534,974View SEC Filing  
10/9/2015James E FlynnInsiderBuy321,785$2.42$778,719.70View SEC Filing  
9/3/2015Calvin W RobertsDirectorBuy6,424$3.00$19,272.006,389View SEC Filing  
8/21/2015Kenneth GreenSVPSell20,000$3.29$65,800.0048,235View SEC Filing  
8/17/2015Kenneth GreenSVPSell20,000$3.90$78,000.0068,235View SEC Filing  
6/26/2015L.P. BavpMajor ShareholderSell1,024$5.00$5,120.00View SEC Filing  
6/19/2015L.P. BavpMajor ShareholderSell5,568$5.00$27,840.00View SEC Filing  
5/1/2015C. Daniel MyersCEOSell2,000$4.37$8,740.00View SEC Filing  
4/27/2015L.P. BavpMajor ShareholderSell3,114$5.02$15,632.28View SEC Filing  
4/23/2015L.P. BavpMajor ShareholderSell4,362$5.00$21,810.00View SEC Filing  
4/20/2015L.P. BavpMajor ShareholderSell30,300$5.03$152,409.00View SEC Filing  
4/15/2015L.P. BavpMajor ShareholderSell35,800$5.03$180,074.00View SEC Filing  
4/14/2015L.P. BavpMajor ShareholderSell18,400$5.01$92,184.00View SEC Filing  
4/13/2015L.P. BavpMajor ShareholderSell100$5.00$500.00View SEC Filing  
3/6/2015Richard S Eiswirth JrCFOBuy10,000$4.84$48,400.00View SEC Filing  
3/2/2015C. Daniel MyersCEOSell2,000$5.21$10,420.00View SEC Filing  
1/2/2015C. Daniel MyersCEOSell2,000$5.51$11,020.00View SEC Filing  
1/2/2015David HollandSVPSell5,000$5.56$27,800.00View SEC Filing  
12/1/2014C. Daniel MyersCEOSell2,000$5.99$11,980.00View SEC Filing  
12/1/2014David HollandSVPSell5,000$5.71$28,550.00View SEC Filing  
10/27/2014L.P. BavpMajor ShareholderSell57,918$6.34$367,200.12View SEC Filing  
10/1/2014C. Daniel MyersCEOSell2,000$5.42$10,840.00View SEC Filing  
10/1/2014David HollandSVPSell5,000$5.26$26,300.00View SEC Filing  
10/1/2014Patrick LeeMajor ShareholderSell621,191$5.42$3,366,855.22View SEC Filing  
9/30/2014Patrick LeeMajor ShareholderSell354,062$5.42$1,919,016.04View SEC Filing  
9/29/2014Patrick LeeMajor ShareholderSell240,662$5.47$1,316,421.14View SEC Filing  
9/11/2014L.P. BavpMajor ShareholderSell2,816$6.25$17,600.00View SEC Filing  
9/4/2014L.P. BavpMajor ShareholderSell39,500$6.33$250,035.00View SEC Filing  
8/29/2014L.P. BavpMajor ShareholderSell7,400$6.27$46,398.00View SEC Filing  
8/28/2014L.P. BavpMajor ShareholderSell3,000$6.27$18,810.00View SEC Filing  
8/1/2014David HollandSVPSell5,000$5.64$28,200.00View SEC Filing  
7/1/2014David HollandSVPSell5,000$6.02$30,100.00View SEC Filing  
5/1/2014David HollandSVPSell5,000$5.93$29,650.00View SEC Filing  
3/4/2014C. Daniel MyersCEOSell22,775$7.10$161,702.50View SEC Filing  
3/4/2014David HollandSVPSell10,000$6.84$68,400.00View SEC Filing  
3/4/2014Susan CaballaInsiderSell8,931$7.01$62,606.31View SEC Filing  
1/16/2014Domain Partners Vi, L.P.Major ShareholderSell296,760$6.39$1,896,296.40View SEC Filing  
7/17/2013Polaris Venture Management CoInsiderSell122,937$4.80$590,097.60View SEC Filing  
6/20/2013Domain Partners Vi, L.P.Major ShareholderSell10,516$5.01$52,685.16View SEC Filing  
6/19/2013Domain Partners Vi, L.P.Major ShareholderSell55,278$5.39$297,948.42View SEC Filing  
6/18/2013Polaris Venture Management CoInsiderSell37,063$5.44$201,622.72View SEC Filing  
6/17/2013Domain Partners Vi, L.P.Major ShareholderSell126,709$5.29$670,290.61View SEC Filing  
6/11/2013Domain Partners Vi, L.P.Major ShareholderSell5,337$5.00$26,685.00View SEC Filing  
5/17/2013David HollandSVPSell30,000$4.13$123,900.00View SEC Filing  
5/16/2013Domain Partners Vi, L.P.Major ShareholderSell44,242$4.60$203,513.20View SEC Filing  
12/13/2012Peter J Pizzo IIIDirectorBuy5,000$1.44$7,200.00View SEC Filing  
12/3/2012C. Daniel MyersCEOSell7,700$1.95$15,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Alimera Sciences (NASDAQ ALIM) News Headlines

Source:
DateHeadline
Alimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on TuesdayAlimera Sciences (ALIM) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 20 at 3:46 AM
Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018Alimera Sciences to Report Fourth Quarter and Full Year 2017 Results on February 28, 2018
finance.yahoo.com - February 14 at 3:24 PM
Alimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 SharesAlimera Sciences, Inc. (ALIM) Major Shareholder Armistice Capital Master Fund Buys 20,000 Shares
www.americanbankingnews.com - February 9 at 9:08 PM
Alimera Sciences (ALIM) Receives "Buy" Rating from HC WainwrightAlimera Sciences (ALIM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - January 22 at 11:54 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) SVP Sells 25,500 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) Insider Sells 13,410 Shares of Stock
www.americanbankingnews.com - January 19 at 10:50 PM
Alimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 SharesAlimera Sciences, Inc. (ALIM) CEO C. Daniel Myers Sells 52,900 Shares
www.americanbankingnews.com - January 19 at 10:30 PM
Alimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in StockAlimera Sciences, Inc. (ALIM) Insider Sells $17,827.62 in Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Philip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) StockPhilip Ashman Sells 25,500 Shares of Alimera Sciences, Inc. (ALIM) Stock
www.americanbankingnews.com - January 18 at 8:30 PM
Insider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of StockInsider Selling: Alimera Sciences, Inc. (ALIM) CEO Sells 52,900 Shares of Stock
www.americanbankingnews.com - January 18 at 8:00 PM
Strongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical ReviewStrongbridge Biopharma (SBBP) vs. Alimera Sciences (ALIM) Critical Review
www.americanbankingnews.com - January 10 at 8:02 AM
Alimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment ResearchAlimera Sciences (ALIM) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - January 8 at 9:26 PM
BRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar CapitalBRIEF-Alimera Sciences Enters Into $40 Mln Term Loan Agreement With Solar Capital
www.reuters.com - January 8 at 3:43 PM
Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital - GlobeNewswire (press release)Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital - GlobeNewswire (press release)
globenewswire.com - January 8 at 8:33 AM
Alimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar CapitalAlimera Sciences Refinances Debt With New $40 Million Debt Facility From Solar Capital
finance.yahoo.com - January 8 at 8:33 AM
Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior ... - StreetInsider.comAlimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior ... - StreetInsider.com
www.streetinsider.com - January 5 at 3:40 PM
Alimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in EuropeAlimera Sciences (ALIM) Announces Acceptance of Filing to Obtain Approval for ILUVIEN Non-Infectious Posterior Uveitis Indication in Europe
www.streetinsider.com - January 4 at 3:38 PM
Alimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in EuropeAlimera Sciences Receives Acceptance of Filing to Obtain Approval for ILUVIEN® Non-Infectious Posterior Uveitis Indication in Europe
finance.yahoo.com - January 4 at 11:14 AM
Alimera Sciences (ALIM) Raised to Sell at ValuEngineAlimera Sciences (ALIM) Raised to Sell at ValuEngine
www.americanbankingnews.com - December 31 at 2:58 PM
ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017ETFs with exposure to Alimera Sciences, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 3:37 PM
Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In IrelandAlimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
finance.yahoo.com - December 11 at 12:04 PM
ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017ETFs with exposure to Alimera Sciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 3:37 PM
Head to Head Analysis: Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)Head to Head Analysis: Alimera Sciences (ALIM) and Novus Therapeutics (NVUS)
www.americanbankingnews.com - December 7 at 1:16 PM
Reviewing Fortress Biotech (FBIO) & Alimera Sciences (ALIM)Reviewing Fortress Biotech (FBIO) & Alimera Sciences (ALIM)
www.americanbankingnews.com - December 4 at 7:39 PM
Alimera Sciences (ALIM) Downgraded by ValuEngine to Strong SellAlimera Sciences (ALIM) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - December 3 at 6:30 AM
Alimera Sciences to Present at the 10th Annual LD Micro ConferenceAlimera Sciences to Present at the 10th Annual LD Micro Conference
finance.yahoo.com - November 28 at 3:36 PM
Alimera Sciences, Inc. (ALIM) Cut to Sell at Zacks Investment ResearchAlimera Sciences, Inc. (ALIM) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 27 at 5:28 PM
Alimera Sciences, Inc. (ALIM) Earns Buy Rating from HC WainwrightAlimera Sciences, Inc. (ALIM) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM
ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017ETFs with exposure to Alimera Sciences, Inc. : November 21, 2017
finance.yahoo.com - November 21 at 4:15 PM
Zacks: Alimera Sciences, Inc. (ALIM) Given Average Recommendation of "Strong Buy" by BrokeragesZacks: Alimera Sciences, Inc. (ALIM) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - November 14 at 1:30 PM
ETFs with exposure to Alimera Sciences, Inc. : November 9, 2017ETFs with exposure to Alimera Sciences, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 4:50 PM
Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology - GlobeNewswire (press release)Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology - GlobeNewswire (press release)
globenewswire.com - November 8 at 6:00 PM
Alimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmologyAlimera Sciences Announces Nine iluvien® data sets to be Presented at 2017 american academy of ophthalmology
finance.yahoo.com - November 8 at 6:00 PM
Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017Alimera Sciences, Inc. :ALIM-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:59 PM
Alimera Sciences CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of ... - GlobeNewswire (press release)Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of ... - GlobeNewswire (press release)
globenewswire.com - November 7 at 10:26 PM
Alimera Sciences CEO Dan Myers to Present During ... - Nasdaq - NasdaqAlimera Sciences' CEO Dan Myers to Present During ... - Nasdaq - Nasdaq
www.nasdaq.com - November 7 at 5:25 PM
Alimera Sciences CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017
finance.yahoo.com - November 7 at 5:25 PM
Edited Transcript of ALIM earnings conference call or presentation 2-Nov-17 1:00pm GMTEdited Transcript of ALIM earnings conference call or presentation 2-Nov-17 1:00pm GMT
finance.yahoo.com - November 5 at 3:45 PM
Alimera Sciences (ALIM) CEO Dan Myers on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaAlimera Sciences' (ALIM) CEO Dan Myers on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 4 at 10:18 PM
Alimera Sciences (ALIM) versus Its Competitors Head to Head ReviewAlimera Sciences (ALIM) versus Its Competitors Head to Head Review
www.americanbankingnews.com - November 3 at 5:32 AM
Alimera Sciences, Inc. 2017 Q3 - Results - Earnings Call SlidesAlimera Sciences, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 2 at 4:08 PM
Alimera Sciences reports 3Q lossAlimera Sciences reports 3Q loss
finance.yahoo.com - November 2 at 4:08 PM
ALIMERA SCIENCES INC to Host Earnings CallALIMERA SCIENCES INC to Host Earnings Call
finance.yahoo.com - November 2 at 4:08 PM
Alimera Sciences, Inc. (ALIM) Earns "Buy" Rating from Cowen and CompanyAlimera Sciences, Inc. (ALIM) Earns "Buy" Rating from Cowen and Company
www.americanbankingnews.com - November 2 at 3:20 PM
Alimera Sciences Reports Third Quarter 2017 Financial Results - NasdaqAlimera Sciences Reports Third Quarter 2017 Financial Results - Nasdaq
www.nasdaq.com - November 1 at 9:08 PM
Alimera Sciences Reports Third Quarter 2017 Financial ResultsAlimera Sciences Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 1 at 9:07 PM
Alimera Sciences, Inc. (ALIM) Receives "Buy" Rating from HC WainwrightAlimera Sciences, Inc. (ALIM) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - October 28 at 12:26 AM
Alimera Sciences to Report Third Quarter 2017 Results November 1st, 2017 - GlobeNewswire (press release)Alimera Sciences to Report Third Quarter 2017 Results November 1st, 2017 - GlobeNewswire (press release)
globenewswire.com - October 26 at 3:42 PM
Alimera Sciences to Report Third Quarter 2017 Results November 1st, 2017 - NasdaqAlimera Sciences to Report Third Quarter 2017 Results November 1st, 2017 - Nasdaq
www.nasdaq.com - October 25 at 4:42 PM
ETFs with exposure to Alimera Sciences, Inc. : October 25, 2017ETFs with exposure to Alimera Sciences, Inc. : October 25, 2017
finance.yahoo.com - October 25 at 4:42 PM

SEC Filings

Alimera Sciences (NASDAQ:ALIM) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Alimera Sciences (NASDAQ:ALIM) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Alimera Sciences (NASDAQ ALIM) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.